We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
-$260M
Cap. Flow
-$71.1M
Cap. Flow %
-2.5%
Top 10 Hldgs %
35.96%
Holding
185
New
14
Increased
26
Reduced
26
Closed
10

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$12.2M
2
SYK icon
Stryker
SYK
+$10.9M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.83M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.51M
5
BDX icon
Becton Dickinson
BDX
+$8.08M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$36.7M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.4M
3
MRK icon
Merck
MRK
+$16.8M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$16.4M
5
DHR icon
Danaher
DHR
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
2 Real Estate 3.21%
3 Industrials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCA icon
26
HCA Healthcare
HCA
$87.2B
$31.2M 1.09%
124,303
+12,342
+11% +$3.1M
SYNH
27
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$30.9M 1.08%
381,570
-21,517
-5% -$1.82M
BIIB icon
28
Biogen
BIIB
$30B
$28.6M 1%
135,639
– –
HUM icon
29
Humana
HUM
$43.7B
$27.7M 0.97%
63,560
-6,100
-9% -$2.55M
ZTS icon
30
Zoetis
ZTS
$32.4B
$26.6M 0.94%
141,167
+18,670
+15% +$3.69M
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$27.5B
$25.9M 0.91%
158,606
-31,089
-16% -$4.74M
BSX icon
32
Boston Scientific
BSX
$69.5B
$25.2M 0.89%
569,398
+33,356
+6% +$1.45M
GH icon
33
Guardant Health
GH
$21.7B
$23.3M 0.82%
351,484
– –
IQV icon
34
IQVIA
IQV
$38.7B
$22.7M 0.8%
98,154
– –
JAZZ icon
35
Jazz Pharmaceuticals
JAZZ
$15.9B
$21.9M 0.77%
140,473
+23,158
+20% +$3.36M
ICLR icon
36
Icon
ICLR
$12.6B
$21.5M 0.75%
88,237
-10,634
-11% -$2.66M
EW icon
37
Edwards Lifesciences
EW
$49.6B
$20.9M 0.73%
177,188
– –
BDX icon
38
Becton Dickinson
BDX
$45.6B
$19.7M 0.69%
75,778
+31,388
+71% +$8.08M
WELL icon
39
Welltower
WELL
$169B
$19.5M 0.69%
203,083
– –
DXCM icon
40
DexCom
DXCM
$31.5B
$18.8M 0.66%
146,684
-21,040
-13% -$2.3M
ZBH icon
41
Zimmer Biomet
ZBH
$18.2B
$18.2M 0.64%
142,044
-4,261
-3% -$514K
ITCI
42
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17.8M 0.63%
290,936
+54,489
+23% +$2.83M
SRPT icon
43
Sarepta Therapeutics
SRPT
$1.57B
$17.8M 0.62%
227,697
-88,200
-28% -$6.75M
CRL icon
44
Charles River Laboratories
CRL
$11.2B
$17.6M 0.62%
61,990
– –
ISRG icon
45
Intuitive Surgical
ISRG
$127B
$17.4M 0.61%
57,606
– –
RMD icon
46
ResMed
RMD
$30.6B
$17.2M 0.6%
70,999
-3,600
-5% -$871K
NVO
47
Novo Nordisk
NVO
$208B
$17M 0.6%
307,046
+70,348
+30% +$3.61M
BNTX icon
48
BioNTech
BNTX
$22.9B
$16.2M 0.57%
95,042
+4,800
+5% +$807K
XLV icon
49
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
$15.5M 0.54%
113,230
– –
VTR icon
50
Ventas
VTR
$48B
$15.3M 0.54%
248,131
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Tekla Capital Management held 185 positions worth $2.85B, down 8.4% from $3.11B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tekla Capital Management's Q1 2022 filing shows 14 new, 26 increased, 26 reduced and 10 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M. The largest sale was Moderna, an estimated $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M.
  • Tekla Capital Management added most to AstraZeneca in Q1 2022, an estimated $12.2M increase.
  • Tekla Capital Management's biggest Q1 2022 reduction was Moderna, cutting an estimated $36.7M.
  • Tekla Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $16.4M.
  • Tekla Capital Management's ten largest holdings make up 36% of its $2.85B portfolio in Q1 2022.
  • Tekla Capital Management opened 14 new positions and closed 10 in Q1 2022.
  • Tekla Capital Management's portfolio value fell 8.4% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.